A new bill introduced in the Maryland House of Delegates requests that pharmas be more specific about the brands related to their otherwise unbranded disease awareness initiatives. More: Maryland bill calls for more transparency in pharma’s disease awareness campaigns Source:
read more
Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions More: Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease Source: News
read moreLynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary cholangitis. More: After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease Source: fierce
read more
Lead Alzheimer’s candidate shows clear biological effects and antidepressant potential More: Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference Source: News
read moreSince investment bank HSBC downgraded the stock of Eli Lilly from “hold” to “reduce” on Tuesday morning, the share price of the Indianapolis drugmaker has dropped by more than 7%. Creating the stir was a note from analyst Rajesh Kumar,
read more
Deal covers up to five candidates including SB36 as company expands global pipeline More: Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals